Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Orthovita, Inc. ("Orthovita" or the "Company") (Nasdaq - VITA) relating to the proposed acquisition by Stryker Corp. ("Stryker").

Under the terms of the transaction, Orthovita shareholders would receive $3.85 in cash for each share of common stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Orthovita by not acting in Orthovita shareholders' best interests in connection with the sale process to Stryker. The transaction may undervalue Orthovita as an analyst has set a price target of $4.00 per share on Orthovita stock.

If you own shares of Orthovita stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com, visiting http://brodsky-smith.com/291-vita-orthovita-inc.html, or by calling toll free 877-LEGAL-90.

Brodsky & Smith, LLC
Jason L. Brodsky, Esquire
Evan J. Smith, Esquire
877-LEGAL-90
investorrelations@brodsky-smith.com
http://brodsky-smith.com/291-vita-orthovita-inc.html